Showing 9,701 - 9,720 results of 18,471 for search 'significantly ((((((less decrease) OR (larger decrease))) OR (a decrease))) OR (mean decrease))', query time: 0.39s Refine Results
  1. 9701

    Image 2_Clinical outcomes of an intelligent pressure-controlled disposable ureteroscope for Laser lithotripsy in renal stone surgery: a retrospective matched cohort study.tif by Zhong Lv (4568410)

    Published 2025
    “…The overall complication rate was significantly lower in the experimental group</p>Conclusions<p>The use of an intelligent pressure-controlled disposable ureteroscope with laser lithotripsy for upper urinary tract surgeries can effectively reduce postoperative inflammation indicators, decrease average hospital stay and renal pelvis pressure, and improve the initial and total stone clearance rates.…”
  2. 9702

    Table1_Radiotherapy plus lenvatinib versus radiotherapy plus sorafenib for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study.docx by Min Zhang (111999)

    Published 2024
    “…The most common adverse events were myelosuppression, decreased liver function, fatigue, diarrhea, nausea, and vomiting. …”
  3. 9703

    Data Sheet 2_Altered gut microbial networks and metabolic pathways in multiple system atrophy: a comparative 16S rRNA study.csv by Po-Chun Liu (676035)

    Published 2025
    “…Additionally, we identified an increase in the ARGORNPROST-PWY pathway (L-arginine degradation, q = 0.003) and a decrease in the PWY-6478 pathway (GDP-D-glycero-α-D-manno-heptose biosynthesis, q = 0.015) in MSA patients compared with HCs.…”
  4. 9704

    Data Sheet 3_Altered gut microbial networks and metabolic pathways in multiple system atrophy: a comparative 16S rRNA study.csv by Po-Chun Liu (676035)

    Published 2025
    “…Additionally, we identified an increase in the ARGORNPROST-PWY pathway (L-arginine degradation, q = 0.003) and a decrease in the PWY-6478 pathway (GDP-D-glycero-α-D-manno-heptose biosynthesis, q = 0.015) in MSA patients compared with HCs.…”
  5. 9705

    Data Sheet 4_Altered gut microbial networks and metabolic pathways in multiple system atrophy: a comparative 16S rRNA study.csv by Po-Chun Liu (676035)

    Published 2025
    “…Additionally, we identified an increase in the ARGORNPROST-PWY pathway (L-arginine degradation, q = 0.003) and a decrease in the PWY-6478 pathway (GDP-D-glycero-α-D-manno-heptose biosynthesis, q = 0.015) in MSA patients compared with HCs.…”
  6. 9706

    Data Sheet 1_Altered gut microbial networks and metabolic pathways in multiple system atrophy: a comparative 16S rRNA study.pdf by Po-Chun Liu (676035)

    Published 2025
    “…Additionally, we identified an increase in the ARGORNPROST-PWY pathway (L-arginine degradation, q = 0.003) and a decrease in the PWY-6478 pathway (GDP-D-glycero-α-D-manno-heptose biosynthesis, q = 0.015) in MSA patients compared with HCs.…”
  7. 9707

    Table 1_Remission of obsessive-compulsive disorder using ketogenic metabolic therapy in support of exposure and response prevention: a retrospective case report.docx by Nicole Laurent (11870390)

    Published 2025
    “…Long-term outcomes were evaluated over a 95-week follow-up.</p>Results<p>Within three weeks of initiating KMT and subsequent ERP, daily compulsive behaviors decreased from 3–8 hours to less than one hour. …”
  8. 9708

    DataSheet1_Positive vaccine beliefs linked to reduced mental stress in healthcare professionals during COVID-19: a retrospective study.pdf by Yu-Yin Lin (19690501)

    Published 2024
    “…Background and aim<p>The COVID-19 pandemic has led to a significant adverse effect on the mental health of healthcare professionals. …”
  9. 9709

    Supplementary Material for: Longer term outcomes of laparoscopic peritoneal lavage in the management of acute Hinchey III perforated diverticulitis: A Systematic review and Meta-An... by Sciascia D. (20480867)

    Published 2024
    “…There was significantly decreased likelihood of having a stoma in the LPL group however there was also a significantly increased likelihood of having recurrent diverticulitis. …”
  10. 9710

    Supplementary Material for: The effectiveness of Long-Term Continuation of Atezolizumab Plus Bevacizumab In Patients Who Receiving Systemic Chemotherapy For Advanced Hepatocellular... by figshare admin karger (2628495)

    Published 2025
    “…Results: According to the periods from the initiation of Atez/Bev to that of the second-line therapy, patients were classified into a long continuation group (Group-L, n = 19), ≥ 11 months; or a short continuation group (Group-S, n = 19), < 11 months. …”
  11. 9711

    Variability of gait features during adaptation. by Samantha Jeffcoat (22783930)

    Published 2025
    “…<p>A) We observed significant differences between groups in step length asymmetry variability during EA. …”
  12. 9712

    DataSheet1_Updated evidence of the Naoshuantong capsule against ischemic stroke: a systematic review and meta-analysis of randomized controlled trials.docx by Cuilin Que (19743256)

    Published 2024
    “…Background<p>Stroke is a serious health issue that can result in death or disability, leading to a significant economic strain on society and families. …”
  13. 9713

    Table 3_Do the diagnosis-related group payment reforms have a negative impact?—an empirical study from Western China.docx by Jia-Yi Wang (490704)

    Published 2025
    “…In the treatment group hospitals, the primary beneficiaries of the reform were urban employees’ basic medical insurance patients, whose costs decreased by 4.9% (p < 0.01), with a non-significant effect on out-of-pocket payment patients and free medical care patients; the hospitals in the treatment group tended to reduce the use of Chinese medicine unique diagnostic and therapeutic means and increase the proportion of western medicine treatments under the pressure of the supremacy of costs.…”
  14. 9714

    Table 2_Do the diagnosis-related group payment reforms have a negative impact?—an empirical study from Western China.xlsx by Jia-Yi Wang (490704)

    Published 2025
    “…In the treatment group hospitals, the primary beneficiaries of the reform were urban employees’ basic medical insurance patients, whose costs decreased by 4.9% (p < 0.01), with a non-significant effect on out-of-pocket payment patients and free medical care patients; the hospitals in the treatment group tended to reduce the use of Chinese medicine unique diagnostic and therapeutic means and increase the proportion of western medicine treatments under the pressure of the supremacy of costs.…”
  15. 9715

    Table 1_Do the diagnosis-related group payment reforms have a negative impact?—an empirical study from Western China.xlsx by Jia-Yi Wang (490704)

    Published 2025
    “…In the treatment group hospitals, the primary beneficiaries of the reform were urban employees’ basic medical insurance patients, whose costs decreased by 4.9% (p < 0.01), with a non-significant effect on out-of-pocket payment patients and free medical care patients; the hospitals in the treatment group tended to reduce the use of Chinese medicine unique diagnostic and therapeutic means and increase the proportion of western medicine treatments under the pressure of the supremacy of costs.…”
  16. 9716

    Image 4_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

    Published 2025
    “…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”
  17. 9717

    Image 2_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

    Published 2025
    “…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”
  18. 9718

    Image 3_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

    Published 2025
    “…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”
  19. 9719

    Table 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.xlsx by Øystein Fluge (200378)

    Published 2025
    “…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”
  20. 9720

    Image 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

    Published 2025
    “…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”